Table 3. Clinicopathological characteristics of the 141 enrolled patients with stage III and IV disease, according to HER2 status.
| Variables | HER2 positive | Heterogeneity vs. Homogeneity p-valuea | HER2 status | Positive vs. Negative p-valuea | ||
|---|---|---|---|---|---|---|
| Heterogeneity (n = 16) | Homogeneity (n = 9) | Positive (n = 25) | Negative (n = 116) | |||
| Age (years) | 0.39b | 0.25b | ||||
| Median | 70.5 | 66.7 | 69.0 | 66.5 | ||
| Range | 47–84 | 51–81 | 47–84 | 38–87 | ||
| Advanced age, % (n) | 0.18c | 0.34c | ||||
| ≥65 years | 81.3 (13) | 55.6 (5) | 72.0 (18) | 62.1 (72) | ||
| Sex, % (n) | 0.14c | 0.43c | ||||
| Male | 62.5 (10) | 88.9 (8) | 72.0 (18) | 63.8 (74) | ||
| Operative method, % (n) | 0.47d | 0.26d | ||||
| Distal gastrectomy | 68.8 (11) | 55.6 (5) | 64.0 (16) | 55.2 (64) | ||
| Total gastrectomy | 31.2 (5) | 33.3 (3) | 32.0 (8) | 42.2 (49) | ||
| Proximal gastrectomy | 0 | 11.1 (1) | 4.0 (1) | 2.6 (3) | ||
| Pathologic TNM stage, % (n) | 0.085d | 0.14c | ||||
| III | 68.8 (11) | 33.3 (3) | 56.0 (14) | 39.7 (46) | ||
| IV | 31.2 (5) | 66.7 (6) | 44.0 (11) | 60.3 (70) | ||
| Lauren classification, % (n) | 0.83c | 0.021c | ||||
| Intestinal type | 62.5 (10) | 66.7 (6) | 64.0 (16) | 38.8 (45) | ||
| Diffuse type | 37.5 (6) | 33.3 (3) | 36.0 (9) | 61.2 (71) | ||
| Depth of tumor invasion, % (n) | 0.48d | 0.11d | ||||
| Muscularis propria | 0 | 11.1 (1) | 4.0 (1) | 3.4 (4) | ||
| Subserosa | 18.7 (3) | 33.3 (3) | 24.0 (6) | 7.8 (9) | ||
| Serosa and peritoneal cavity | 75.0 (12) | 55.6 (5) | 68.0 (17) | 81.0 (94) | ||
| Adjacent structures | 6.3 (1) | 0 | 4.0 (1) | 7.8 (9) | ||
| Lymphatic invasion, % (n) | 0.29d | 0.53d | ||||
| ly0 | 0 | 11.1 (1) | 4.0 (1) | 2.6 (3) | ||
| ly1 | 18.7 (3) | 0 | 12.0 (3) | 23.3 (27) | ||
| ly2 | 37.5 (6) | 55.6 (5) | 44.0 (11) | 35.3 (41) | ||
| ly3 | 43.8 (7) | 33.3 (3) | 40.0 (10) | 38.8 (45) | ||
| Venous invasion, % (n) | 0.86d | 0.087d | ||||
| v0 | 0 | 0 | 0 | 5.2 (6) | ||
| v1 | 25.0 (4) | 22.2 (2) | 24.0 (6) | 31.0 (36) | ||
| v2 | 18.7 (3) | 33.3 (3) | 24.0 (6) | 37.9 (44) | ||
| v3 | 56.3 (9) | 44.5 (4) | 52.0 (13) | 25.9 (30) | ||
aResults were considered statistically significant when p-values were less than 0.05.
bt-test.
cchi-square test.
dFisher’s exact test.
Abbreviation: HER2, human epidermal growth factor receptor 2.